The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-sev ...

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients ...

Corvus Pharmaceuticals develops next-gen ITK inhibitors, with promising Phase 1 results. Read why CRVS stock can thrive in ...

According to newly published research, the exposure to nature provided by the Re-Connecting Nature forest microbe extract has ...

“Red light therapy is an energy-based modality that uses specific wavelengths of red and near-infrared light (typically ...

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Read the entire package insert before using this ...

China: A recent analysis from the National Health and Nutrition Examination Survey (NHANES) 2005–2006 revealed that ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) with or without asthma and allergic rhinitis in young children.

Corvus Pharmaceuticals (NASDAQ:CRVS) lost ~34% in the premarket on Wednesday after the company announced early results from a ...

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profileData includes complete results from ...

Corvus Pharmaceuticals (CRVS) announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating ...